跳至主要内容
临床试验/NL-OMON40689
NL-OMON40689招募中不适用

Endovascular Renal Sympathetic Denervation using the Boston Scientific Vessix V2 renal denervation system to Improve Heart Failure - IMPROVE-HF-I

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Age >=18 years;
  • 2. Systolic ejection fraction (established on echo) <35%;
  • 3. NYHA Class II, III or IV heart failure despite optimal heart failure therapy;
  • 4. Renal arteries suitable for the proposed treatment;
  • 5. A glomerular filtration rate of 30ml/min/1.73m2 or more;
  • 6. Written informed consent;
  • 7. The patient agrees to the follow-up.

排除标准

  • 1. Pregnancy;
  • 2. Renal artery abnormalities;
  • 3. Acute heart failure;
  • 4. A systolic office based blood pressure of <110mmHg systolic;
  • 5. Recent (<3months) stroke or myocardial infarction
  • 6. Hypertrophic obstructive cardiomyopathy, constrictive pericarditis
  • 7. The patient has other medical illness (i.e., cancer) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with limited life expectancy (i.e., less than one year);

研究者

相似试验